Prolor Biotech

Intellectual Property

Back to Technologies  

We license the CTP intellectual property necessary to develop CTP-based drug candidates from Washington University of St. Louis pursuant to a License Agreement. The License Agreement is exclusive for human therapeutics, with the right to sub-license, for all therapeutic proteins and peptides, of natural or non-natural sequence, other than four endocrine proteins - LH, FSH, TSH and hCG, previously licensed to Merck & Co., a leading pharmaceutical company.

In addition, we have been issued by the U.S. Patent Office the following CTP-related patents:

  • Three new proprietary patents covering our long-acting hGH drug candidate (2009, 2011)

  • A new CTP platform patent covering CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high affinity protein ligands, proteins that induce or regulate an immune response, proteins that are involved with autocrine and paracrine activities, and mimetics of these therapeutic proteins, as well as other types of proteins (2011)

  • CTP-modified interferons (2011) 
 

We also license intellectual property necessary to develop RevPEG drug candidates from the Weizmann Institute of Science (Israel) pursuant to a License Agreement.  

We have filed several other patent applications covering our platforms and drug candidates in the U.S. and other territories.